PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2316.2009-000		APPLICATION NO. 10/786,380	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION  November 4, 2005  (Use several sheets if necessary)	FIRST NAMED INVENTOR Mary Jane Cardosa		FILING DATE February 24, 2004	
	EXAMINER Not Yet Assigned			GROUP 1642

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
мм		C24	Mayr, A., et al., "Abstammung, Eigenschaften und Verwendung des Attenuierten Vaccinia-Stammes MVA," Infection, 3:6-14 (1975).				
		C25	Megret, et al., "Use of Recombinant Fusion Proteins and Monoclonal Antibodies to Define Linear and Discontinuous Antigenic Sites on the Dengue Virus Envelope Glycoprotein", Virology 187:480-491 (1992).				
		C26	Meyer, H., et al., "Mapping of Deletions in the Genome of the Highly Attenuated Vaccinia Virus MVA and their Influence on Virulence," J. Gen. Virol., 72:1031-1038 (1991).				
		C27	Moss, B., et al., "New mammalian expression vectors," Nature 348(6296): 91-92 (1990).				
		C28	NTIS Accession Number PB, 88201363, "Novel Recombinant Vaccinia Virus Expression Vectors and Method of Selecting Same". (1988)				
		C29	NTIS Accession Number PB89144802, "Novel Inhibitor of HIV Infection". (1988)				
		C30	NTIS Accession Number PB88192059, " A Synthetic Antigen Evoking Anti-HIV Response". (1988)				
		C31	Pupo-Antunez, Maritza et al., "Monoclonal Antibodies Raised to the Dengue-2 Virus (Cuban: A15 Strain) Which Recognize Viral Structural Proteins," Hybridoma, 16(4): 347-353 (1997).				
		C32	Scheiflinger, et al., "Evaluation of the Thymidine Kinase (TK) Locus as an Insertion Site in the Highly Attenuated Vaccinia MVA Strain," Arch. Virol. 141:663-669 (1996).				
		C33	Smucny, JJ., et al., "Murine Immunoglobulin G Subclass Responses Following Immunization With Live Dengue Virus or a Recombinant Dengue Envelope Protein," Am J. Trop Med. Hyg. 53(4):432-437 (1995).				
		C34	Stickl, H., et al., "MVA-Stufenimpfung Gegen Pocken" Disch. Med. Wschr., 99:2386-2392 (1974).				
		C35	Sutter, G., et al., "A Recombinant Vector Derived from the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus," Vaccine, 12(11):1032-1040 (1994).				
	/	C36	Sutter, G. and Moss, B., "Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes," Proc. Natl. Acad. Sci., USA, 89:10847-10851 (1992).				

EXAMINER /Mary Mosher/	DATE CONSIDERED 09/18/2006

1 22407